Causaly Launches AI-powered Competitive Intelligence Application for Research Scientists
New Pipeline Graph unifies competitive insights with preclinical research on a single AI platform to accelerate drug target identification and...
Pharmaceutical
TAG1 and PharmaLogic Announce Strategic Partnership to Advance Decentralized Lead-212 Generator Development
Collaboration accelerates TAG1's Pb-212 generator development and supports PharmaLogic's mission to scale radiopharmaceutical innovation. ST. LOUIS, June 24, 2025 /PRNewswire/...
MellingMedical Teams Up with Zynex Medical to Expand Access to Non-Invasive Pain Management Solutions Across Federal Healthcare System
Strategic agreement brings innovative electrotherapy and orthotic solutions to America's veterans, active duty and DoD personnel ALEXANDRIA, Va., June 24,...
Mark Hensley joins RBL LLC as a senior adviser
HOUSTON, June 24, 2025 /PRNewswire/ -- RBL LLC, a pioneering biotech venture creation studio designed to rapidly build companies based...
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or...
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch...
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
Enrollment is now underway across multiple clinical sites, in partnership with Syneos HealthVANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) --...
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight...
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced...
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage...
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a...
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on...
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company...
Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile Ethics approval and Phase 1 clinical trial start...
Starton Therapeutics and Bend Bioscience Enter into Development Agreement for Oral Controlled Release Dosage Form of STAR-LLD (lenalidomide)
PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their...
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
- RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for...
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request...